Attention Deficits After Brain Injury: An Overlooked Long-Term Challenge
Each year, Brain Injury Awareness Day reminds us not only of the immediate impact of traumatic brain injury (TBI), but also of the long-term consequences that often remain undetected. Among these, attention deficits stand out as one of the most persistent and life-altering challenges faced by patients who have suffered a brain injury.
Attention is a fundamental cognitive function that influences nearly every aspect of daily life—from maintaining conversations and completing tasks to making decisions and staying safe. After a brain injury, many patients experience difficulty in
- Sustaining focus
- Filtering distractions or
- Switching attention between tasks
These impairments are not simply inconveniences. They can significantly affect independence, employability, social relationships and overall quality of life.
What makes post-TBI attention deficits particularly challenging is their chronic nature. While physical injuries may heal, cognitive deficits often persist for months or even years. Patients frequently describe mental fatigue, slower information processing and an inability to cope with complex or busy environments. These symptoms can lead to frustration, reduced confidence, and in some cases, social isolation or depression.
Despite the burden, attention deficits have historically been under-diagnosed and undertreated in long-term brain injury care. Rehabilitation strategies such as cognitive training and behavioral therapy remain essential, but there is growing recognition that pharmacological support can play a meaningful role in recovery.
One such option is Cerebrolysin®, a neuropeptide-based cerebroprotective agent that has been studied for its potential to support neurorecovery following brain injury. Its multimodal mechanism—targeting neuroprotection, neuroplasticity and neuronal repair—aligns with the complex pathophysiology of TBI, where diffuse and evolving damage affects multiple cognitive domains, including attention.
Importantly, Cerebrolysin® is not just an experimental concept; it is supported by clinical evidence and has been incorporated into the Evidence-Based Review of Acquired Brain Injury (ERABI) guidelines in Canada with a 1B recommendation and was recognized and mentioned in the highly respected International Cognitive (INCOG) group guidelines. These guidelines recognize Cerebrolysin’s role in improving cognitive outcomes, including attention, in individuals recovering from brain injury. This inclusion reflects a growing consensus that addressing cognitive deficits requires both rehabilitative and pharmacological treatment concepts.
As we observe Brain Injury Awareness Day, it is crucial to broaden the conversation beyond survival to long-term recovery and quality of life. Attention deficits may be invisible, but their impact is profound. By increasing awareness, supporting research and integrating evidence-based treatments like Cerebrolysin® into care pathways, we can offer patients not just hope—but tangible improvements in their cognitive function and daily lives.